Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study-Reference-Cited by-同舟云学术

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study

Published:2019-03-14 Issue:6 Volume:98 Page:1435-1440
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Jullien Maxime,Trudel Sabrina,Tessoulin Benoit,Mahé Béatrice,Dubruille Viviane,Blin Nicolas,Gastinne Thomas,Bonnet Antoine,Lok Anne,Lebourgeois Amandine,Peterlin Pierre,Garnier Alice,Chevalier Patrice,Guillaume Thierry,Thomaré Patrick,Le Gouill Steven,Moreau Philippe,Touzeau Cyrille

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-019-03655-5.pdf

Reference14 articles.

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520. https://doi.org/10.1182/blood-2007-10-116129

2. Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM (2017) Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia 31:2443–2448. https://doi.org/10.1038/leu.2017.138

3. Touzeau C, Moreau P, Dumontet C (2017) Monoclonal antibody therapy in multiple myeloma. Leukemia 31:1039–1047. https://doi.org/10.1038/leu.2017.60

4. Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NWCJ, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG (2015) Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373:1207–1219. https://doi.org/10.1056/NEJMoa1506348

5. de Weers M, Tai Y-T, van der Veer MS et al (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol Baltim Md 1950 186:1840–1848. https://doi.org/10.4049/jimmunol.1003032

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience;Annals of Hematology;2024-05-28

2. Advances in the Treatment of Extramedullary Multiple Myeloma;Journal of Clinical Personalized Medicine;2024

3. Multiple Myeloma in 2023 Ways: From Trials to Real Life;Current Oncology;2023-11-03

4. Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis;Haematologica;2022-10-06

5. Advances in the treatment of extramedullary disease in multiple myeloma;Translational Oncology;2022-08